Rosetta Genomics Ltd. terminated its planned merger with Genoptix Inc. after failing to secure majority shareholder approval for the deal.

The Israeli genomic diagnostics company said that about 47% of its shareholders voted, with about 66% in favor of the deal.

Following the deal termination, Rosetta will reimburse $750,000 of Genoptix's expenses in three installments as provided by the merger agreement.

Genoptix has indicated that it remains interested in pursuing alternative options to consummate a transaction with Rosetta.